16
Participants
Start Date
August 7, 2019
Primary Completion Date
December 11, 2019
Study Completion Date
PRV-3279 or placebo
bi-specific antibody-based molecule
Clinical site, Baltimore
Provention Bio, Inc.
INDUSTRY